LCTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...

Stats
本日の出来高	313 340
平均出来高	962 704
時価総額	214.93M
EPS	$0 ( 2024-03-07 )
次の収益日	( $-0.0400 ) 2024-05-09
Last Dividend	$0.0800 ( 2003-12-15 )
Next Dividend	$0 ( N/A )
P/E	-9.50
ATR14	$0.00300 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Culley Brian M	Buy	1 900 000	Employee Stock Option (Right to Buy)
2024-03-07	Samuel George A. Iii	Buy	650 000	Employee Stock Option (Right to Buy)
2024-03-07	Howe Jill Ann	Buy	650 000	Employee Stock Option (Right to Buy)
2024-02-11	Samuel George A. Iii	Sell	6 076	Restricted Stock Units
2024-02-11	Samuel George A. Iii	Buy	6 076	Common Shares, no par value

INSIDER POWER
98.14
Last 93 transactions
Buy: 20 710 358 \| Sell: 1 476 683

ボリューム相関

長: 0.21 (neutral)

短: -0.13 (neutral)

Signal:(58.928) Neutral

Lineage Cell Therapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Lineage Cell Therapeutics 相関 - 通貨/商品

-0.45
( neutral )

-0.18
( neutral )

0.00
( neutral )

0.31
( neutral )

Lineage Cell Therapeutics 財務諸表

Annual	2023
収益:	$8.95M
総利益:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2023
収益:	$8.95M
総利益:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2022
収益:	$14.70M
総利益:	$13.98M (95.05 %)
EPS:	$-0.160

FY	2021
収益:	$3.90M
総利益:	$2.47M (63.40 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Lineage Cell Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0800	2003-12-15
Last Dividend	$0.0800	2003-12-15
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0800	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
BTG	Ex Dividend Knight	2023-09-20	Quarterly	0.00%
FCO	Ex Dividend Knight	2023-09-21	Monthly	0.00%
NBW	Ex Dividend Knight	2023-09-28	Monthly	0.00%
VFL	Ex Dividend Knight	2023-09-21	Monthly	0.00%
BCV	Ex Dividend Junior	2023-09-14	Quarterly	0.00%
ERC	Ex Dividend King	2023-09-11	Monthly	0.00%
LNG	Ex Dividend Knight	2023-08-08	Quarterly	0.00%
SIFI	Ex Dividend Junior	2023-09-01	Bi-Monthly	0.00%
DIT	Ex Dividend Knight	2023-08-03	Bi-Monthly	0.00%
JAVA	Ex Dividend Junior	2023-09-19	Bi-Monthly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.213	1.200	-7.10	-8.52	[0 - 0.3]
returnOnEquityTTM	-0.313	1.500	-4.59	-6.89	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.14	0.800	4.30	3.44	[1 - 3]
quickRatioTTM	2.02	0.800	2.84	2.27	[0.8 - 2.5]
cashRatioTTM	1.973	1.500	0.148	0.222	[0.2 - 2]
debtRatioTTM	0.0292	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	56.86	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0847	-0.169	[0 - 20]
debtEquityRatioTTM	0.0465	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.905	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-2.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-9.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0885	0.800	-2.74	-2.19	[0.5 - 2]
Total Score				-0.295

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.15	1.000	-1.025	0	[1 - 100]
returnOnEquityTTM	-0.313	2.50	-2.95	-6.89	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0564	-0.169	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0593	1.500	-2.94	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.19	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.30

Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.